COMMUNIQUÉS West-GlobeNewswire

Dividend payment ex-date of AS “Olainfarm”
29/06/2018
Dividend payment ex-date of AS “Olainfarm” AS “Olainfarm” (OLF1R, ISIN code LV0000100501) will close the list of shareholders for dividend payment on July 4, 2018 at the end of the working day of the Nasdaq CSD Latvian [...]
NICOX : Point sur les récents progrès de ses programmes et activités clés
29/06/2018
Communiqué de presse Nicox : Point sur les récents progrès de ses programmes et activités clés ............................................. 29 juin 2018 - diffusion à 7h30 Sophia Antipolis, France Nicox S.A. (Euronext [...]
Nicox Highlights Recent Progress with Key Programs and Activities
29/06/2018
Press Release Nicox Highlights Recent Progress with Key Programs and Activities .............................................. June 29, 2018 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: [...]
Sensorion Shows Protective Effect of SENS-401 in Hearing Loss Models
29/06/2018
MONTPELLIER, France, June 29, 2018 (GLOBE NEWSWIRE) -- Sensorion ( FR 0012596468 – ALSEN ), a biotech company specializing in the treatment of inner ear diseases , presented data showing that its clinical stage product- [...]
VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members
29/06/2018
Valneva Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members Lyon (France), June 29, 2018 - Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial [...]
VALNEVA annonce le succès de son Assemblée Générale et le renouvellement des mandats de son directoire
29/06/2018
Valneva annonce le succès de son Assemblée Générale et le renouvellement des mandats de son directoire Lyon (France), June 29, 2018 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au [...]
Sanofi: CHMP recommends approval of Cablivi(TM) (caplacizumab)
29/06/2018
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) CHMP recommends approval of Cablivi(TM) (caplacizumab) First therapeutic to receive positive CHMP opinion for treatment of a rare blood disorder called acquired [...]
Sanofi : Le CHMP recommande l'approbation du Cablivi(TM) (caplacizumab)
29/06/2018
Communiqué de presse Source : Sanofi (EURONEXT : SAN) (NYSE : SNY) Le CHMP recommande l'approbation du Cablivi(TM) (caplacizumab) Premier agent thérapeutique à obtenir un avis favorable du CHMP pour le traitement d'un [...]
Novartis announces intention to seek shareholder approval for 100% spinoff of Alcon eye care devices business; initiates share buyback of up to USD 5 bn
29/06/2018
Alcon strategic review concludes that 100% spinoff in best interest of shareholders and consistent with the Novartis strategy of focusing as a medicines company Planned spinoff would create world leading eye care [...]
Novartis annonce son intention de solliciter l'approbation des actionnaires pour la scission à 100% d'Alcon, sa division de produits ophtalmologiques, et initie un rachat d'actions à hauteur d'USD ...
29/06/2018
L'examen stratégique d'Alcon conclut qu'une scission à 100% serait dans l'intérêt des actionnaires et en ligne avec la stratégie de Novartis visant à se concentrer sur son activité pharmaceutique La scission prévue [...]
Zomedica Announces Interim Closing and Extension of Its Private Offering of Common Shares
29/06/2018
ANN ARBOR, Mich., June 28, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V:ZOM) (the “Company”), a veterinary diagnostic and pharmaceutical company, announced today that it has [...]
Precision Therapeutics Signs Definitive Merger Agreement with Helomics Holding Corporation
29/06/2018
MINNEAPOLIS, June 28, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery [...]
RavenQuest Announces Non-Brokered Private Placement
28/06/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS VANCOUVER, British Columbia, June [...]
GenMark Diagnostics Announces FDA Submission of its ePlex Blood Culture Identification Gram Positive Panel
28/06/2018
First of Three ePlex Molecular Multiplex Panels for the Diagnosis and Management of Bloodstream Infections That Can Lead to Sepsis CARLSBAD, Calif., June 28, 2018 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: [...]
Topline results of PELICAN trial and update on triple combo development plans
28/06/2018
First trial to evaluate C2 corrector GLPG2737 in CF patients treated with Orkambi GLPG2737 achieved primary efficacy endpoint and was well-tolerated in patients Significant further reduction in sweat chloride [...]
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig® (erenumab) in patients with chronic and episodic migraine
28/06/2018
Results from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be presented at AHS Aimovig [...]
Mount Tam Biotechnologies Announces Appointment of New Member to the Board of Directors
28/06/2018
NOVATO, CA, June 28, 2018 (GLOBE NEWSWIRE) -- Mount Tam Biotechnologies, Inc. ("Mount Tam" or the “Company”) (OTC PINK: MNTM), a company focused on the discovery and development of novel mTOR inhibitors, is pleased to [...]
Voyager Therapeutics Appoints Andre Turenne as President and Chief Executive Officer
28/06/2018
CAMBRIDGE, Mass., June 28, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today [...]
Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata
28/06/2018
WAYNE, Pa., June 28, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to [...]

Pages